Inhaled bronchodilators for the prevention and treatment of chronic lung disease in preterm infants

CONCLUSIONS: Low-certainty evidence from one trial showed that inhaled bronchodilator prophylaxis may result in little or no difference in the incidence of mortality or CLD in preterm infants, when compared to placebo. The evidence is very uncertain about the effect of salbutamol on pneumothorax, and neither included study reported on the incidence of serious adverse effects. We identified no trials that studied the use of bronchodilator therapy for the treatment of CLD. Additional clinical trials are necessary to assess the role of bronchodilator agents in the prophylaxis or treatment of CLD. Researchers studying the effects of inhaled bronchodilators in preterm infants should include relevant clinical outcomes in addition to pulmonary mechanical outcomes.PMID:38591664 | PMC:PMC11002972 | DOI:10.1002/14651858.CD003214.pub4
Source: Cochrane Database of Systematic Reviews - Category: General Medicine Authors: Source Type: research